Neuroblastoma and ALK signalling
Background
Genomic alterations in the Anaplastic Lymphoma Kinase (ALK) receptor tyrosine kinase have been identified high-risk neuroblastoma, the most common cancer during infancy. New targeted therapeutic approaches, including tyrosine kinase inhibitors that target ALK, show promising results. However, not all ALK-positive cancers respond to ALK inhibition and drug resistance is a major clinical problem. Combinatorial therapies, targeting different ALK signaling molecules offer a strategy to circumvent these problems but require thorough insights in downstream ALK signaling pathways.
What we do
Our goal is to better understand the effect of different molecular perturbations on the dynamics of ALK signaling in neuroblastoma and related cancers and use these insights to identify new combinatorial treatment options. This project is a multidisciplinary and international collaboration with teams from Ghent University (Speleman lab) as well as the University of Gothenburg, Sweden (Palmer lab and Hallberg lab).
Who is involved
Jonatan
Gabre
PhD Student
Joachim
Siaw
Postdoc
Peter
Merseburger
PhD Student
Jimmy
Van den Eynden
Principal Investigator
Research output
Mar 22, 2024
6th Neuroblastoma Research Symposium 2024
A spatial transcriptomic exploration of the neuroblastoma TME in response to ATR inhibition - Peter Merseburger
Jan 11, 2024
Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEAN
Jonatan L Gabre, Peter Merseburger, Arne Claeys, Joachim Siaw, Sarah-Lee Bekaert, Frank Speleman, Bengt Hallberg, Ruth H Palmer and Jimmy Van den Eynden
Jan 5, 2024
Nederlandse Anatomen Vereniging conference 2024
The application of spatial transcriptomics to determine the tumor microenvironment response to experimental drugging in neuroblastoma mice models - Peter Merseburger
Dec 28, 2023
ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition
Marcus Borenäs, Ganesh Umapathy, Dan E. Lind, Wei-Yun Lai, Jikui Guan, Joel Johansson, Eva Jennische, Alexander Schmidt, Yeshwant Kurhe, Jonatan L. Gabre, Agata Aniszewska, Anneli Strömberg, Mats Bemark, Michael N. Hall, Jimmy Van den Eynden, Bengt Hallberg and Ruth H. Palmer
Nov 15, 2023
EMBL Cancer Genomics Conference 2023
Peter Merseburger, Jonatan Gabre, Joachim Siaw
Feb 15, 2023
ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression
Tzu-Po Chuang, Wei-Yun Lai, Jonatan Gabre, Dan E. Lind, Ganesh Umapathy, Abdulmalik A. Bokhari, Bengt Bergman, Linnea Kristenson, Fredrik B. Thorén, Anh Le, Robert C. Doebele, Jimmy Van den Eynden, Ruth H. Palmer and Bengt Hallberg
Jul 24, 2022
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC
A.A. Bokhari, W-Y. Lai, A.T. Le, Jonatan Gabre, T-P. Chuang, S. Fransson, B. Bergman, A. Djos, N. Chen, T. Martinsson, Jimmy Van den Eynden, R.C. Doebele, R.H. Palmer, B. Hallberg and G. Umapathy
Nov 24, 2021
ATR inhibition enables complete tumour regression in ALK-driven NB mouse models
Joanna Szydzik, Dan E. Lind, Badrul Arefin, Yeshwant Kurhe, Ganesh Umapathy, Joachim Siaw, Arne Claeys, Jonatan Gabre, Jimmy Van den Eynden, Bengt Hallberg and Ruth H. Palmer
Apr 15, 2021
Loss of RET promotes mesenchymal identity in neuroblastoma cells
Joachim T. Siaw, Jonatan Gabre, Ezgi Uçkun, Marc Vigny, Wancun Zhang, Jimmy Van den Eynden, Bengt Hallberg, Ruth H. Palmer and Jikui Guan
Jan 7, 2021
ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation
Marcus Borenäs, Ganesh Umapathy, Wei‐Yun Lai, Dan E Lind, Barbara Witek, Jikui Guan, Patricia Mendoza‐Garcia, Tafheem Masudi, Arne Claeys, Tzu‐Po Chuang, Abeer El Wakil, Badrul Arefin, Susanne Fransson, Jan Koster, Mathias Johansson, Jennie Gaarder, Jimmy Van den Eynden, Bengt Hallberg and Ruth H Palmer
Sep 22, 2020
11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma
Joachim Tetteh Siaw, Niloufar Javanmardi, Jimmy Van den Eynden, et al.